title: Circulating tumor cell technologies.
abstract: Circulating tumor cells, a component of the "liquid biopsy", hold great potential to transform the current landscape of cancer therapy. A key challenge to unlocking the clinical utility of CTCs lies in the ability to detect and isolate these rare cells using methods amenable to downstream characterization and other applications. In this review, we will provide an overview of current technologies used to detect and capture CTCs with brief insights into the workings of individual technologies. We focus on the strategies employed by different platforms and discuss the advantages of each. As our understanding of CTC biology matures, CTC technologies will need to evolve, and we discuss some of the present challenges facing the field in light of recent data encompassing epithelial-to-mesenchymal transition, tumor-initiating cells, and CTC clusters.
authors.affiliation: Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
authors.forename: Meghaan M
authors.initials: MM
authors.lastname: Ferreira
authors.affiliation: Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
authors.forename: Vishnu C
authors.initials: VC
authors.lastname: Ramani
authors.affiliation: Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: ssj@stanford.edu.
authors.forename: Stefanie S
authors.initials: SS
authors.lastname: Jeffrey
mesh_terms: D000818:Animals; D002469:Cell Separation / Q000295:instrumentation / Q000379:methods*; D002498:Centrifugation / Q000295:instrumentation / Q000379:methods; D004586:Electrophoresis / Q000295:instrumentation / Q000379:methods; D005374:Filtration / Q000295:instrumentation / Q000379:methods; D006801:Humans; D056656:Lab-On-A-Chip Devices; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D009360:Neoplastic Cells, Circulating / Q000473:pathology*
keywords: Antigen-independent enrichment; CTC capture; CTC clusters; Cancer; Immunoaffinity enrichment